Last reviewed · How we verify
NCT04915352: NPT-MAR
Interest of Nasal Provocation Tests for Diagnosis of House Mites Allergic Rhinitis
Phase 4 trial testing Nasal provocation test - 725 Dermatophagoides Pteronyssinus in Mite Allergy in 8 participants. Terminated before completion.
5 July 2024
Quick facts
| Lead sponsor | Centre Hospitalier Régional Metz-Thionville |
|---|---|
| Phase | Phase 4 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 8 |
| Start date | 7 March 2022 |
| Primary completion | 5 July 2024 |
| Estimated completion | 5 July 2024 |
| Sites | 1 location across France |
Drugs / interventions tested
- Nasal provocation test - 725 Dermatophagoides Pteronyssinus — full drug profile →
- Negative control — full drug profile →
Conditions studied
- Mite Allergy — all drugs for Mite Allergy →
- Respiratory Disease — all drugs for Respiratory Disease →
Sponsor
Centre Hospitalier Régional Metz-Thionville
Who can join
18 and older, any sex, with Mite Allergy or Respiratory Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this clinical trial is to compare the positive predictive value of the combination rapid nasal provocation test (RNTP) + skin tests (TC) + specific immunoglobulins E (IgEs) to the combination of TC + IgEs (strategy currently used in clinical practice) concerning the efficacy of treatment with Allergen immunotherapy (ITA) at 1 year, in patients with symptoms suggesting allergic rhinitis to house dust mites.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04915352
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Centre Hospitalier Régional Metz-Thionville trials
Trials by the same sponsor.
- NCT07435389 — VENTILATION DURING SPACEFLIGHT (PHASE 2) · NA · not yet recruiting
- NCT07405996 — Referral of Patients With Biological Abnormalities to an Emergency Department · not yet recruiting
- NCT07406022 — Optical Characterization and Multi-modality, Multi-scale Modeling of Human Skin Applied to Cancer Diagnosis. · not yet recruiting
- NCT07515404 — A New Multimodal and Semi-specific Therapeutic Plasmapheresis Concept, a Case Series Study · completed
- NCT07390604 — Case Series : Management of Elevated Lipoprotein(a) Using Double-Filtration Plasmapheresis (DFPP) in Hemodialysis Patien · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04915352 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Régional Metz-Thionville
- Last refreshed: 9 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04915352.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing